These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 8062531

  • 1. Interpretive criteria for DU-6859a disk diffusion tests using 5-micrograms disks.
    Jones RN, Johnson DM, Erwin ME.
    Diagn Microbiol Infect Dis; 1994 Feb; 18(2):125-7. PubMed ID: 8062531
    [Abstract] [Full Text] [Related]

  • 2. Interpretive criteria for CI-960 (AM-1091, PD127391) disk diffusion tests using 5-microgram disks.
    Jones RN, Erwin ME, Barrett MS.
    Diagn Microbiol Infect Dis; 1992 Feb; 15(4):379-81. PubMed ID: 1319303
    [Abstract] [Full Text] [Related]

  • 3. In vitro activity of DU-6859a, a new fluorocyclopropyl quinolone.
    Marshall SA, Jones RN.
    Antimicrob Agents Chemother; 1993 Dec; 37(12):2747-53. PubMed ID: 8109948
    [Abstract] [Full Text] [Related]

  • 4. Interpretive criteria for susceptibility tests with DU-6859a and FK-037 tested against Haemophilus influenzae and Neisseria gonorrhoeae.
    Jones RN, Barrett MS, Biedenbach DJ.
    Diagn Microbiol Infect Dis; 1994 Jun; 19(2):93-9. PubMed ID: 7805362
    [Abstract] [Full Text] [Related]

  • 5. Preliminary interpretive criteria for in vitro susceptibility testing of CP-99219 by dilution and disk diffusion methods.
    Jones RN.
    Diagn Microbiol Infect Dis; 1994 Nov; 20(3):167-70. PubMed ID: 7874885
    [Abstract] [Full Text] [Related]

  • 6. Modifications for disk diffusion susceptibility testing criteria of clinafloxacin (CI-960, AM-1091, PD127371) and fleroxacin (Ro 23-6240, AM-833) following studies with a challenge panel of ciprofloxacin-resistant clinical isolates.
    Jones RN, Johnson DM.
    Diagn Microbiol Infect Dis; 1995 Apr; 21(4):209-13. PubMed ID: 7554803
    [Abstract] [Full Text] [Related]

  • 7. The effects of increasing levels of quinolone resistance on in-vitro activity of four quinolones.
    Thomson KS, Sanders CC.
    J Antimicrob Chemother; 1998 Aug; 42(2):179-87. PubMed ID: 9738835
    [Abstract] [Full Text] [Related]

  • 8. Reevaluations of disk diffusion susceptibility testing interpretive criteria for lomefloxacin and norfloxacin using fluoroquinolone-resistant isolates.
    Cormican MG, Jones RN.
    Diagn Microbiol Infect Dis; 1995 Apr; 21(4):227-30. PubMed ID: 7554807
    [Abstract] [Full Text] [Related]

  • 9. Activity of two novel fluoroquinolones (DU-6859a and DV-7751a) tested against glycopeptide-resistant enterococcal isolates.
    Jones RN, Johnson DM, Biedenbach DJ, Marshall SA.
    Diagn Microbiol Infect Dis; 1995 Nov; 23(3):123-7. PubMed ID: 8849658
    [Abstract] [Full Text] [Related]

  • 10. Multi-center validation of proposed disk diffusion susceptibility testing interpretive criteria for lomefloxacin using more than 1,500 clinical isolates.
    Cormican MG, Erwin MS, Jones RN.
    Diagn Microbiol Infect Dis; 1996 Mar; 24(3):169-72. PubMed ID: 8724404
    [Abstract] [Full Text] [Related]

  • 11. In vitro activities of clinafloxacin against contemporary clinical bacterial isolates from 10 North American centers.
    Fuchs PC, Barry AL, Brown SD.
    Antimicrob Agents Chemother; 1998 May; 42(5):1274-7. PubMed ID: 9593166
    [Abstract] [Full Text] [Related]

  • 12. DU-6859a, a new fluoroquinolone agent. Comparative in vitro activity against enteric pathogens and multiresistant outpatient Escherichia coli.
    Tomayko JF, Korten V, Murray BE.
    Diagn Microbiol Infect Dis; 1994 Sep; 20(1):45-7. PubMed ID: 7867298
    [Abstract] [Full Text] [Related]

  • 13. [Evaluation of proposed criteria of disk susceptibility testing for tosufloxacin and lomefloxacin in NCCLS guidelines and WHO standards].
    Aihara M, Oguri T, Kanno H, Kubo S, Honda M, Satoh K, Daimon Y, Yamanaka K, Sugawara K, Furuta T.
    Rinsho Byori; 1992 Jan; 40(1):73-80. PubMed ID: 1312183
    [Abstract] [Full Text] [Related]

  • 14. In vitro activity of DU-6859a against anaerobic bacteria.
    Wexler HM, Molitoris E, Reeves D, Finegold SM.
    Antimicrob Agents Chemother; 1994 Oct; 38(10):2504-9. PubMed ID: 7840599
    [Abstract] [Full Text] [Related]

  • 15. Cross-resistance analysis for DU-6859a, a new fluoroquinolone, compared to six structurally similar compounds (ciprofloxacin, clinafloxacin, fleroxacin, levofloxacin, ofloxacin, and sparfloxacin).
    Cormican MG, Marshall SA, Jones RN.
    Diagn Microbiol Infect Dis; 1995 Jan; 21(1):51-4. PubMed ID: 7789097
    [Abstract] [Full Text] [Related]

  • 16. In-vitro comparison of DU-6859a, a novel fluoroquinolone, with other quinolones and oral cephalosporins tested against 5086 recent clinical isolates.
    Marshall SA, Jones RN, Murray PR, Washington JA, Allen SD, Gerlach EH, Erwin ME.
    J Antimicrob Chemother; 1993 Dec; 32(6):877-84. PubMed ID: 8144428
    [No Abstract] [Full Text] [Related]

  • 17. Suggested modifications for disk diffusion susceptibility testing criteria for levofloxacin and sparfloxacin following tests with a predictor panel of ciprofloxacin-resistant clinical isolates.
    Sutton LD, Jones RN.
    J Clin Microbiol; 1995 Jan; 33(1):146-8. PubMed ID: 7699031
    [Abstract] [Full Text] [Related]

  • 18. Comparison of in vitro activities of DU-6859a and other fluoroquinolones against Japanese isolates of anaerobic bacteria.
    Kato N, Kato H, Tanaka-Bando K, Watanabe K, Ueno K.
    Clin Infect Dis; 1996 Dec; 23 Suppl 1():S31-5. PubMed ID: 8953104
    [Abstract] [Full Text] [Related]

  • 19. In vitro activity of the aryl-fluoroquinolones A-56619 and A-56620 and evaluation of disk susceptibility tests.
    Barry AL, Jones RN, Thornsberry C, Ayers LW, Gavan TL, Gerlach EH.
    Eur J Clin Microbiol; 1986 Feb; 5(1):18-22. PubMed ID: 2938944
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.